CTIC
Income statement / Annual
Last year (2022), CTI BioPharma Corp.'s total revenue was $53.95 M,
and the percentage change from the previous year is not available.
In 2022, CTI BioPharma Corp.'s net income was -$91.04 M.
See CTI BioPharma Corp.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$53.95 M
|
$0.00
|
$0.00
|
$3.35 M
|
$26.29 M
|
$25.15 M
|
$57.41 M
|
$16.12 M
|
$60.08 M
|
$34.68 M
|
| Cost of Revenue |
$3.51 M |
$161,000.00 |
$4.20 M |
$0.00 |
$879,000.00 |
$364,000.00 |
$1.38 M |
$1.94 M |
$895,000.00 |
$137,000.00 |
| Gross Profit |
$50.43 M |
-$161,000.00 |
-$4.20 M |
$3.35 M |
$25.41 M |
$24.78 M |
$56.03 M |
$14.18 M |
$59.18 M |
$34.54 M |
| Gross Profit Ratio |
0.93 |
0 |
0 |
1 |
0.97 |
0.99 |
0.98 |
0.88 |
0.99 |
1 |
| Research and Development
Expenses |
$36.90 M
|
$39.14 M
|
$25.94 M
|
$24.11 M
|
$36.47 M
|
$32.87 M
|
$64.96 M
|
$76.63 M
|
$86.46 M
|
$33.62 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$17.63 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$84.83 M
|
$56.20 M
|
$17.63 M
|
$19.16 M
|
$21.18 M
|
$31.44 M
|
$45.31 M
|
$53.96 M
|
$56.24 M
|
$42.29 M
|
| Other Expenses |
$8.51 M |
-$161,000.00 |
$4.20 M |
$1.32 M |
$0.00 |
$0.00 |
-$5.08 M |
$253,000.00 |
$2.72 M |
$155,000.00 |
| Operating Expenses |
$130.23 M |
$95.33 M |
$47.77 M |
$43.26 M |
$57.65 M |
$64.30 M |
$105.19 M |
$130.84 M |
$145.42 M |
$75.91 M |
| Cost And Expenses |
$133.75 M |
$95.33 M |
$47.77 M |
$43.26 M |
$58.53 M |
$64.67 M |
$106.57 M |
$132.78 M |
$146.31 M |
$76.05 M |
| Interest Income |
$1.68 M |
$38,000.00 |
$204,000.00 |
$1.17 M |
$1.22 M |
$0.00 |
-$2.61 M |
-$2.10 M |
$0.00 |
$0.00 |
| Interest Expense |
$13.14 M |
$2.42 M |
$1.03 M |
$1.52 M |
$1.73 M |
$2.04 M |
$2.83 M |
$2.49 M |
$2.68 M |
$1.54 M |
| Depreciation &
Amortization |
-$56,000.00
|
-$161,000.00
|
$204,000.00
|
$3.29 M
|
$593,000.00
|
$717,000.00
|
$831,000.00
|
$990,000.00
|
$1.10 M
|
$1.57 M
|
| EBITDA |
-$79.85 M
|
-$95.33 M
|
-$47.77 M
|
-$37.43 M
|
-$32.90 M
|
-$39.52 M
|
-$49.16 M
|
-$116.67 M
|
-$86.23 M
|
-$39.63 M
|
| EBITDA Ratio |
-1.48 |
0 |
0 |
-11.19 |
-1.03 |
-1.51 |
-0.84 |
-7.19 |
-1.49 |
-1.14 |
| Operating Income Ratio
|
-1.48
|
0
|
0
|
-12.17
|
-1.25
|
-1.57
|
-0.86
|
-7.24
|
-1.44
|
-1.2
|
| Total Other
Income/Expenses Net |
-$13.20 M
|
-$2.58 M
|
-$4.68 M
|
$688,000.00
|
$3.55 M
|
-$1.31 M
|
-$3.79 M
|
-$4.10 M
|
-$8.00 M
|
-$2.02 M
|
| Income Before Tax |
-$92.99 M |
-$97.91 M |
-$52.45 M |
-$40.02 M |
-$29.35 M |
-$40.83 M |
-$52.95 M |
-$120.76 M |
-$94.23 M |
-$43.55 M |
| Income Before Tax Ratio
|
-1.72
|
0
|
0
|
-11.97
|
-1.12
|
-1.62
|
-0.92
|
-7.49
|
-1.57
|
-1.26
|
| Income Tax Expense |
-$1.95 M |
$1.73 M |
$500,000.00 |
$2.29 M |
$5.28 M |
$723,000.00 |
-$963,000.00 |
-$1.60 M |
-$5.32 M |
-$485,000.00 |
| Net Income |
-$91.04 M |
-$99.64 M |
-$52.95 M |
-$42.32 M |
-$29.32 M |
-$40.67 M |
-$52.01 M |
-$119.42 M |
-$93.37 M |
-$42.74 M |
| Net Income Ratio |
-1.69 |
0 |
0 |
-12.65 |
-1.12 |
-1.62 |
-0.91 |
-7.41 |
-1.55 |
-1.23 |
| EPS |
-0.79 |
-1.11 |
-0.74 |
-0.73 |
-0.52 |
-1.12 |
-1.86 |
-4.26 |
-6.29 |
-3.74 |
| EPS Diluted |
-0.79 |
-1.11 |
-0.74 |
-0.73 |
-0.52 |
-1.12 |
-1.86 |
-4.26 |
-6.29 |
-3.74 |
| Weighted Average Shares
Out |
$114.69 M
|
$90.12 M
|
$71.14 M
|
$57.97 M
|
$56.07 M
|
$36.45 M
|
$27.95 M
|
$28.05 M
|
$14.85 M
|
$11.42 M
|
| Weighted Average Shares
Out Diluted |
$114.69 M
|
$90.12 M
|
$71.14 M
|
$57.97 M
|
$56.07 M
|
$36.45 M
|
$27.95 M
|
$28.05 M
|
$14.85 M
|
$11.42 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
